CREB-binding protein (CBP) and p300 are highly homologous transcriptional coactivators with unique, non-redundant roles that bind a wide array of proteins, including catenins-β and γ. ICG-001 is a small-molecule inhibitor that specifically inhibits the CBP/catenin interaction. Importantly, ICG-001 does not inhibit the p300/catenin interaction. We demonstrate that specifically inhibiting the interaction between CBP and catenin with ICG-001 results in the differentiation of quiescent drug-resistant chronic myelogenous leukemia-initiating cells (CML LICs), thereby sensitizing them to BCR-ABL tyrosine kinase inhibitors, for example, Imatinib. Using ICG-001 in a NOD/SCID/IL2Rγ − / − mouse model of engrafted human chronic myelogenous leukemia, we now demonstrate the complete elimination of engrafted leukemia after only one course of combined chemotherapy. Combinationtreated animals live as long as their non-engrafted littermates. Results from these studies demonstrate that specifically antagonizing the CBP/catenin interaction with ICG-001 can eliminate drug-resistant CML LICs without deleterious effects to the normal endogenous hematopoietic stem cell population.
INTRODUCTION Despite the stunning clinical success achieved to date in treating chronic-phase (CP) chronic myelogenous leukemia (CML), responses in advanced-phase patients treated with the BCR-ABL antagonist Gleevec/Imatinib (IM) are often short-lived, and patients generally undergo disease progression. 1 Even patients demonstrating complete response to IM therapy are not cured, as discontinuation of IM treatment frequently results in relapse. Furthermore, resistance to IM develops in 2-4% of patients annually and IM dose escalation is generally not sufficient to control the disease. 2 Several mechanisms that contribute to tyrosine kinase inhibitor (TKI) resistance have been proposed, including the insensitivity of quiescent CML stem cells to TKIs owing to low expression of BCR-ABL. 3 Increased nuclear β-catenin has been observed with progression to blast crisis (BC), 4 a hallmark of increased Wnt/β-catenin transcription. 5 Leukemiainitiating cells (LICs) are insensitive to TKIs, and additionally, genomic instability in this subpopulation is a significant concern. 6 Although deletion of β-catenin after CML initiation does not significantly affect survival in mice, deletion of β-catenin has been shown to synergize with IM and abrogate CML stem cells. 7 Aberrant Wnt signaling is associated with many cancers, including CML. 8 Many Wnt signaling-related genes are upregulated in CML, especially in association with disease progression. 9 Genes that are critically involved in oncogenesis, including survivin, have been identified to be regulated by the activation of Wnt/catenin-mediated transcription. 10, 11 Epigenetic silencing of negative regulators of the Wnt signaling cascade is also frequently associated with leukemias, including CML. 12 β-Catenin signaling is also activated during the development of MLL (mixed-lineage leukemia) leukemic stem cells. 13 Wnt signaling is classically mediated through β-catenin, 14 which in turn recruits the Kat3 coactivators, CREB-binding protein (CBP) or its closely related homolog EP300 (p300), as well as other components of the basal transcriptional apparatus. 15, 16 The distinct roles of the coactivators CBP and p300 in self-renewal and differentiation, respectively, has been documented. [17] [18] [19] [20] This has also been confirmed at the genome-wide level using chromatin immunoprecipitation sequencing (ChIP-seq). 21 Using a hematopoietic stem cell (HSC) model, Livingston and co-workers concluded that CBP, but not p300, is essential for HSC self-renewal, whereas p300 is critical for proper hematopoietic differentiation. 17, 22 Additionally, Kawasaki et al. 23 found that p300, but not CBP, is absolutely required for retinoic acid-induced F9 teratocarcinoma cell differentiation. Utilizing the specific small-molecule CBP/catenin antagonist ICG-001, we previously demonstrated that CBP and p300 have distinct functions in the regulation of β-catenin-mediated gene transcription including, c-myc, Cyclin D1, 24 EphB2 25 and survivin/BIRC5, 10 the fourth most upregulated transcript in cancer. 26 The molecular mechanism of ICG-001 has been previously described. Briefly, it modulates Wnt/catenin signaling by specifically binding to CBP, but not p300, thereby disrupting the CBP/catenin interaction and thus downregulating CBP/catenin-mediated transcription. 24, 27, 28 The high-affinity, specific binding of ICG-001 to CBP subsequently leads to transiently increased p300/catenin interaction and thereby upregulation of p300/catenin-mediated gene transcription. 10, 24, 25, [27] [28] [29] [30] [31] The minimal ICG-001-binding region on CBP has been mapped to amino acids 1-110 at the N-terminus; interestingly, the least homologous region between the two coactivators.
The controversial dichotomous behavior of Wnt/catenin signaling in controlling both maintenance of potency and differentiation in stem/progenitor cells can be readily explained through our model of differential coactivator usage by catenin-that is, CBP usage by catenin leads to the transcriptional activation of cassettes of genes that are involved in the maintenance of stem/progenitor cell potency and self-renewal; whereas the use of the coactivator p300 leads to activation of genes involved in the initiation of differentiation 28, 29 (Supplementary Figure S1 ). The use of p300 by catenin as a coactivator can be pharmacologically induced by CBP/catenin antagonists, for example, ICG-001, 24, 25 thereby initiating differentiation in a wide variety of systems 25, 28, 30, 31 and eliminating cancer stem-like cells in both mouse genetic models 19 and drug-resistant human primary B-ALL (acute B lymphoblastic leukemia). 20 In this report, we demonstrate that IM-resistant (IM-R) CML cells exhibit characteristics consistent with a quiescent LIC population. Our data also indicate that when the quiescent IM-R population is treated with the CBP/catenin antagonist ICG-001, it initiates a myeloid differentiation pathway. Treating this cell population with ICG-001 induces their differentiation, both in vitro and in vivo, thereby sensitizing these quiescent drug-resistant cells to IM. Eliminating the LIC population via forced differentiation dramatically increases the effectiveness of BCR-ABL antagonist chemotherapy both in vitro and in vivo in murine models of CML. A CBP/catenin antagonist in combination with the BCR-ABL antagonist Nilotinib completely eliminates engrafted CML in NSG mice, without any apparent deleterious effects to the normal HSC population as judged by both hematopoietic parameters and overall lifespan compared with their non-irradiated, nonengrafted, untreated littermates.
RESULTS

IM-R CML cells are enriched in LIC
The oncoprotein BCR-ABL is the molecular target for TKIs, such as IM and second-generation agents Dasatinib and Nilotinib. However, the insensitivity of quiescent LICs to TKIs constitutes a significant problem. Rather than trying to prospectively identify LICs via specific cell surface markers, 4, 32, 33 we chose to initiate our investigations using primary CML patients' samples, which we treated in vitro with IM to identify drug-resistant populations. IM resistance correlates with the emergence of drug-resistant LICs and is associated with increased nuclear catenin levels and enhanced Wnt/catenin transcription. 5 We anticipated that the drug-resistant cell population would be enriched in LICs relative to the drug-sensitive population. Treatment in vitro with 1 μM IM for 6-12 days was used to select resistant cells. IM-treated versus control-treated samples were analyzed by fluorescence-activated cell sorter (FACS). DAPI (4,6-diamidino-2-phenylindole) was used to exclude dead cells. We consistently observed an IM-R population in all primary CML samples tested-both bone marrow and leukopheresis samples. This was true regardless of whether the patient had previously received IM chemotherapy or was chemotherapy naive. IM-R cells were consistently characterized as being DAPI negative, low forward and low side scatter (DAPI neg /F low /S low ; Figure 1a , upper panel). In contrast, the IM-sensitive (IM-S) cells were DAPI negative but exhibited both higher forward and side scatter (DAPI neg /F hi /S hi ). Enrichment of the IM-R cell population could be achieved by treatment with IM in a dose-dependent manner (Supplementary Figure S2A ). Cell cycle analysis revealed that approximately 65 times more IM-S cells compared with IM-R cells are in S phase (13% versus 0.2%, respectively). Furthermore, 96% of IM-R cells were in the G0/G1 phase of the cell cycle versus 72% of the IM-S cells (Figure 1a , lower panel). BrdU (bromodeoxyuridine) incorporation and Ki67 staining were consistent with the cell cycle analysis (Figure 1b ). These data are consistent with the IM-R cells having a highly quiescent, blast-like phenotype.
Recent studies have revealed that multi-drug-resistance genes, including MDR-1, ABCG2, and ABCA3, are intrinsically expressed in stem/progenitor cells from multiple adult tissues and that they contribute to the Side Population (SP) phenotype of malignant cells. 34, 35 Wnt/catenin signaling appears to have an important role in ABCB1/MDR-1 transcription and multi-drug resistance, 36 and in particular, CBP/catenin signaling is critical to maintain the SP. 37 We therefore utilized Hoechst 33342 dye exclusion to identify the SP cells in the same CML patient samples. Again, consistent with enrichment in LICs, IM-R cells contributed to the majority of SP cells in CML samples-77% versus 23% for IM resistant versus IM sensitive (Supplementary Figure S2B) .
We next examined the expression of BCR-ABL in both IM-S and IM-R populations using quantitative real-time-PCR (qRT-PCR). BCR-ABL gene expression is significantly (three times) lower in IM-R cells compared with IM-S cells (Figure 1c ). This was anticipated, as it has been previously demonstrated that IM does not eliminate the CML LIC population. Both CML LICs and the IM-R cell population do not depend on the BCR-ABL oncoprotein for their survival. 38 We next sorted IM-R (1.6 × 10 5 ) and IM-S (2×10 5 ) cells and engrafted them into NOD/SCID/IL2Rγ − / − (NSG) mice. After 6 months, the mice were killed and the peripheral blood, bone marrow and spleen were analyzed to determine the engraftment of the human leukemic cells. In five out of five mice that received IM-R cells, we could readily detect human CD45 + cell engraftment ( Figure 1d ). In sharp contrast, none of the seven mice that received IM-S cells demonstrated any human CD45 + cell engraftment at 6 months. BCR-ABL expression was confirmed by RT-PCR in all human CD45 + samples collected. This confirmed that the IM-R population was enriched in LICs compared with the IM-S population.
CML LICs do not require BCR-ABL for their survival; 38 however, as they differentiate and become transient-amplifying cells and expand, they increase their expression of this oncoprotein. We therefore performed a series of experiments to determine whether the IM-R cell population, upon differentiation and expansion, also increased its expression of BCR-ABL, similar to the LIC population. When IM-R cells were cultured for 4 days on the murine stromal cell line M2-10B4, BCR-ABL expression was significantly increased by 10-fold ( Figure 1e ). In colony-formation cell (CFC) assays using freshly isolated IM-R cells, we could not detect any CFC activity, unlike the IM-S cells ( Figure 1f ). However, after co-culture on stroma for 5 weeks, IM-R cells acquired significant colony-forming activity ( Figure 1g ). We conclude that differentiating the primitive, quiescent IM-R cell population on stroma generated transientamplifying cells that expressed BCR-ABL and were competent to generate colonies.
Inhibiting the CBP/catenin interaction initiates differentiation in CML LIC ICG-001 by binding to the amino terminus of the coactivator CBP blocks the interaction between CBP and catenins-both β and γ. 24, 39 This results in decreased transcription of CBP/catenindependent genes that are associated with tumor cell survival (for example, survivin), 26 with a concomitant increase in the expression of genes associated with cellular differentiation (for example, EphB2). 25 We examined three CML patients' samples, two BC and one IM resistant, for βand γ-catenin expression in subcellular fractions by immunoblotting (Supplementary Figure  S3 ). In two of the three patients' samples, there is significantly increased nuclear γ-catenin. Next, we examined Wnt/catenin (β-or γ-catenin) coactivator usage-either CBP or p300-by co-immunoprecipitation assay in both IM-R and IM-S cell populations. Treatment with IM has previously been shown to Figure 1 . (a) Primary CML cells were cultured in QBSF-60 serum-free medium with or without IM (1 μM) for 6-12 days. Cells were then analyzed by FACS for cell viability (DAPI was used for dead cell exclusion). The IM-R population in all primary CML samples tested was consistently DAPI negative, low forward and low side scatter (DAPI neg /F low /S low ). The IM-S population was DAPI negative but demonstrated both higher forward and side scatter (DAPI neg /F hi /S hi ) (upper panel). Cell cycle analysis using propidium iodide showed that there were approximately 65 times more cells in S phase of the cell cycle in the IM-S population (13%) compared with the IM-R cell population (0.2%). This analysis also demonstrated that 72% of the sensitive population was in G0/G1 phase compared with the IM-R cell population in which 96% of the cells were in G0/G1 phase (lower panel). Representative results from a BC patient sample are shown. Similar results were obtained from three CML patient samples ( Supplementary Table S2 ). significantly increase γ-catenin expression. 10, 39 After in vitro treatment of CML cells with IM, the majority of nuclear catenin was γ-catenin in IM-R cells and was essentially exclusively associated with CBP ( Figure 2a , lanes 7 versus 8). Little or no catenin can be detected in association with either coactivator in IM-S cells (Figure 2a , lanes 5 and 6). When LICs differentiate, there is a concomitant upregulation of BCR-ABL expression. 40 ICG-001 is a potent initiator of differentiation in stem/progenitor cells; 19, 20, 27, 31, 41 we therefore evaluated BCR-ABL expression in the IM-R LIC population. We treated BC CML patient samples with ICG-001 and examined the expression of BCR-ABL and survivin/BIRC5. An inhibitor of apoptosis protein, survivin is the fourth most upregulated transcript in cancer and is associated with chemotherapy resistance, increased tumor recurrence and poor prognosis. 11, 42 As shown in Figure 2b , ICG-001 treatment resulted in a dramatic increase in BCR-ABL message in IM-R cells, with a 50% reduction in survivin message in the IM-R population as well as a smaller reduction in IM-S cells. Based on these results, we anticipated that ICG-001 would re-sensitize IM-R CML cells to IM. 20 Inhibition of CBP/catenin interaction re-sensitizes resistant cells to IM CML patient samples were first treated with ICG-001 prior to IM treatment. As expected, ICG-001 treatment alone did not cause significant cell death ( Supplementary Table S1 ). However, there was a significant increase in apoptosis in the dual treated cells (ICG-001 pretreated, followed by IM), as compared with IM only treated cells ( Figure 2c ). Next, we tested 17 primary CML samples -9 CP patients, 4 BC patients and 4 patients who had failed IM therapy. These samples were pretreated with either ICG-001 or dimethyl sulfoxide (DMSO) control for 2 days and then exposed to low dose IM (0.2 μM) for 2 days. Again, ICG-001 treatment alone did not result in significant cell death. However, in both IM naive samples, as well as samples from patients who had failed IM chemotherapy, cells pretreated with ICG-001 responded to IM more effectively, compared with cells pretreated with the DMSOvehicle control as judged by increased apoptosis (Figure 2d ). Downregulation of CBP/catenin signaling with ICG-001 treatment, as anticipated, resulted in decreased survivin expression with a concomitant increase in BCR-ABL expression, thereby making the cells BCR-ABL dependent, and thus more sensitive to IM. It is also important and worth noting that the BC/failed IM samples were also more responsive to IM after ICG-001 treatment.
Inhibiting the CBP/catenin interaction eliminates CML LICs We next investigated the effects of ICG-001 on colony-forming activity. When primary unsorted patient samples were treated with 10 μM ICG-001 for 2 days, the CFC numbers were significantly decreased compared with the DMSO control samples (Figure 2e , upper panel). When patient samples were treated with IM and ICG-001 combination, this essentially eliminated colony-forming activity (Figure 2e , lower panel).
To determine in vitro which subset of the CML cell population was most sensitive to ICG-001, we treated patient samples with IM alone, ICG-001 alone or in combination and analyzed the viability of the IM-R (DAPI neg /F low /S low ) and the IM-S (DAPI neg /F hi /S hi ) Figure 2f ). Furthermore, as anticipated ICG-001 also decreased the side population in these samples (Figure 2g ).
Inhibiting CBP/catenin interaction eliminates CML LIC engraftment in NSG mice
Having determined that ICG-001 can sensitize drug-resistant CML LICs to IM in vitro, we wanted to investigate the ability of ICG-001 to eliminate drug-resistant LIC in vivo. For these studies, we first selected two well-characterized CML cell lines that were derived from BC patients-K562 cells were sensitive to IM, whereas EM2 cells were resistant to IM (Supplementary Figure S4A ). We initially characterized the effects of ICG-001 on K562 and EM2 cells in vitro. Similar to our results with CML patient samples, ICG-001 treatment decreased survivin and increased BCR-ABL expression in both K562 and EM2 cells at both the mRNA ( Figure 3a ) and protein level ( Figure 3b ). Similar to the biochemical specificity data previously reported in other cell types, 24 when CML cells were treated with ICG-001, the CBP/catenin interaction was specifically disrupted (Figure 3c . Furthermore, as demonstrated by ChIP, there was a decrease in CBP with concomitantly increased p300 occupancy at the human survivin promoter in the presence of ICG-001 ( Figure 3d ). Although ICG-001 treatment alone did not cause significant cell death in either line, treatment sensitized both K562 and EM2 cells to IM-induced apoptosis after ICG-001 treatment (Supplementary Figure S4B ). ICG-001 treatment also significantly decreased CFC capacity and the side population ( Supplementary Figures S4C and D) .
We also evaluated the effects of ICG-001 on cell differentiation. Treatment of K562 cells with ICG-001 for 3 days increased the cell (Figure 3e ). Taken together, the data demonstrates that ICG-001 by disrupting the CBP/catenin interaction initiates a differentiative pathway with upregulation of BCR-ABL expression, thereby improving the efficacy of BCR-ABL antagonists. Long-term and secondary engraftment are hallmarks of both LICs and normal HSCs. To examine the ability of a CBP/catenin antagonist to eliminate drug-resistant LICs, we performed a series of experiments. We marked EM2 cells with a lentiviral luciferase expression vector and then treated these cells in vitro with either ICG-001 or DMSO for 5 days prior to engraftment in NSG mice. ICG-001-and DMSO-treated EM2 cells were subcutaneously transplanted into the first-generation recipients. The transplanted cells were viable and proliferative as judged by imaging ( Figure 3f ). After 20 days, 5 × 10 4 leukemia cells were recovered from the engrafted primary recipients and transplanted into the bone marrow of secondary recipients. In the DMSO control group, the secondary transplantation was uniformly successful (4/4) and all of the mice were dead by day 53. In stark contrast, none of the mice in the ICG-001-pretreated group successfully engrafted, even after extended periods of observation (128 days; Figure 3f ). This data demonstrate that, after only 5 days of in vitro treatment with ICG-001, the LIC population had been eliminated as judged by the lack of bone marrow engraftment, even though leukemic cell viability was seemingly not affected, based on in vivo imaging at day 20. This suggests that ICG-001 treatment eliminates the LIC population by differentiating LIC to 'bulk' CML cells, without killing this 'bulk' population.
Furthermore, even allowing the cells to proliferate untreated for 20 days subcutaneously in vivo, there were no evidence of non-LICs reverting to an LIC phenotype. This experiment, together with previous studies with the CBP/catenin antagonist ICG-001, at least partially addresses concerns about the plasticity of the CSC/LIC phenotype and their therapeutic elimination. 20, 37, 43 However, as this experiment consisted of an in vitro pretreatment, concerns regarding the potential deleterious effects of CBP/catenin antagonists on the normal HSC pool still needed to be addressed.
CBP/catenin antagonism safely eliminates CML LIC in vivo
To alleviate these concerns and to monitor leukemia engraftment and progression in vivo, we marked K562 cells with the lentiviral luciferase expression vector and transplanted these cells into the bone marrow of NSG mice. Leukemia engraftment was detected by day 13 and subsequently the mice were randomized into three treatment groups-phosphate-buffered saline (PBS) only (control), PBS plus Nilotinib and ICG-001 plus Nilotinib (Figure 4a ). The second-generation and more potent TKI Nilotinib was utilized in Pharmacological CML stem cell elimination Y Zhao et al this experiment, owing to its enhanced bioavailability in mice compared with IM. 44 All groups received one 28-day course of treatment (from posttransplantation day 13 to day 41). At the end of this treatment period, the control PBS-treated mice showed continuously increasing levels of luciferase activity, whereas the luciferase signal in the PBS/Nilotinib-as well as the ICG-001/ Nilotinib-treated groups had decreased to baseline levels (Figure 4a ). However, by day 63, approximately 20 days after treatment had stopped, the luciferase signal in the PBS/Nilotinib group was detectable again, and the signal continued to increase (Figure 4a ). This result was not surprising, and has also been observed clinically after cessation of treatment, as BCR-ABL antagonists are not able to eliminate the CML LIC population. 4 In sharp contrast, the ICG-001/Nilotinib combination treatment group continued to show baseline luciferase levels, with no increase in luciferase signals even at the termination of monitoring.
The median lifespan after CML transplantation in the Nilotinibtreated group was 235 days versus 73 days in the PBS control group. Nilotinib-only-treated mice demonstrated significantly increased survival when compared with the PBS control-treated animals. However, all the mice in the PBS control group, as well as in the Nilotinib only group, were dead by days 110 and 260 after transplantation, respectively (Figure 4b ). Importantly, in the ICG-001/Nilotinib combination-treated group, all the mice survived significantly longer than the Nilotinib-only-treated group. All the mice in the ICG-001/Nilotinib combination treatment group have essentially the same lifespan as their healthy littermate controls, which had never been engrafted with leukemia ( Figure 4b) .
To confirm the absence of the BCR-ABL transcripts in the peripheral blood of the ICG-001/Nilotinib combination-treated mice, PCR was performed using samples that were collected 330 days after cessation of treatment. As shown, no BCR-ABL 5 and 7) . The upper panel was probed with an antibody recognizing both CBP and p300; the middle panel was probed with an antibody specific to γ-catenin; the lower panel was probed with an antibody specific to β-catenin. (d) K562 cells were treated with DMSO or ICG-001 (either 10 or 20 μM) for 24 h for ChIP analysis, using normal IgG, anti-CBP (A22) or anti-p300 (N15). qPCR was subsequently performed to determine the change in occupancy by CBP and p300 in the human survivin/BIRC5 proximal promoter region. ICG-001 decreased CBP but increased p300 occupancy on the human survivin promoter. The results are the average of two experiments. (e) K562 cells were treated with ICG-001 (10 μM) for 3 days and then harvested for FACS analysis of multiple myeloid surface markers (CD11b, CD16, CD33 and CD56) and the megakaryocyte marker CD41. The light gray peaks represent the DMSO-treated samples; the darker gray peaks represent the ICG-001-treated samples. (f) EM2 cells marked with a lentiviral luciferase vector were pretreated in vitro for 5 days with either DMSO control or ICG-001 (10 μM) before being subcutaneously implanted into primary recipient NSG mice. The implanted cells expanded and were viable in vivo in the case of both treatments. After 20 days, 5 ×10 4 cells were recovered from the engrafted primary recipients and transplanted into the bone marrow of secondary recipient NSG mice via tail-vein injection. In the DMSO group, secondary transplantation was uniformly successful (4/4) and all of the mice died by day 53. In stark contrast, none of the mice (4/4) in the ICG-001-pretreated group successfully engrafted even after 128 days of observation. (Figure 4c, lanes 1-5) . Importantly, the mice from the ICG-001/ Nilotinib combination treatment group also exhibited a normal hematopoietic profile as judged by red blood cell, white blood cell, platelet counts and hemoglobin measurements, similar to and essentially all within the normal range compared with their agematched, non-irradiated, non-engrafted, non-treated control littermates (Figure 4d ). Finally, we engrafted two primary human CML patient samples into NSG mice. Having confirmed the engraftment based upon FACS analysis at day 14 (Supplementary Figure S5) , mice were randomized to the Nilotinib or Nilotinib plus ICG-001 treatment groups, and a 28-day course of treatment was initiated. Similar to the results observed with the engrafted K562 cells, the combination treatment of ICG-001/Nilotinib demonstrated significant improvement in overall survival compared with the mice in the Nilotinib only group. The median survival time for the first Nilotinib only group was 108 days. However, all the mice in the ICG-001/Nilotinib group were still alive at the time of killing almost 200 days after bone marrow transplantation, indicating the combination treatment significantly extended lifespan (P = 0.0018, Figure 4e , lower panel). The second sample group provided similar results. One hundred and ninety days after leukemia transplantation, only one of the five mice in the Nilotinib only group survived (median survival 169 days), while five of the six mice in the ICG-001/Nilotinib-treated group survived (P = 0.045, Figure 4e , upper panel).
DISCUSSION
The ability to safely eliminate the drug-resistant LIC population, without damaging endogenous normal stem cell populations, is critical to the development of more effective chemotherapeutic strategies and complete elimination of leukemia. We have recently reported that selective disruption of the CBP/β-and γ-catenin interactions using ICG-001 leads to differentiation of pre-B-ALL cells and loss of self-renewal capacity in primary drug-resistant patient samples. 20 Similarly, ICG-001 initiates the differentiation of salivary gland tumor-propagating cells in a mouse genetic model (gain-of-function Wnt signaling/loss-of-function BMPR1 signaling) and decreases H3K4me3 at promoters of stem cell-associated genes in vitro. 19 In this paper, we demonstrate that ICG-001, by specifically antagonizing the interaction between CBP and catenin in CML, results in the initiation of a differentiative pathway. This is manifested by the increased expression of the myeloid and megakaryocyte differentiation markers-CD11b, CD16, CD33, CD56 and CD41 (Figure 3e ). CBP/catenin antagonists, for example, ICG-001, being initiators of differentiation are not cytotoxic and therefore only very limited apoptosis is observed when used as a single agent ( Supplementary Table S1 ). The forced differentiation of LICs leads to decreased expression of the antiapoptotic gene survivin and a concomitant increase in the expression of oncoprotein BCR-ABL, a hallmark of CML. These combined observed effects on LICs after treatment with ICG-001-including downregulation of survivin and upregulation of BCR-ABL-are associated with elimination via forced differentiation of quiescent LICs into a 'bulk' CML population that is sensitive to BCR-ABL antagonists, thereby enabling complete elimination of leukemia.
CML patient samples similarly show that ICG-001 leads to decreased survivin expression not only in the IM-R but also, albeit less, in the IM-S population. Pretreatment of CML cells in vitro with ICG-001 eliminated, essentially irreversibly, 37 the LIC population, as judged by the lack of bone marrow engraftment into NSG mice, even though this pretreatment did not decrease cell viability (Figure 3f ). Importantly, ICG-001 in combination with Nilotinib, can safely eliminate engrafted leukemia of both primary CML patient samples, as well as K562 cells, in NSG mice, without any apparent deleterious effects to the normal endogenous HSC population, as judged by normal hematopoietic parameters and normal life span.
We have shown that ICG-001, a specific CBP/catenin antagonist, by inhibiting the interaction between catenins and CBP, results in transient increased binding of p300/catenin, leading to the initiation of a differentiative pathway (Supplementary Figure S1 ). 27, 28 Treatment with CBP/catenin antagonist leads to the differentiation of tumor-initiating cells, as well as the downregulation of survivin levels. This renders the differentiated progeny sensitive to current chemotherapeutic agents. Modulation of this fundamentally critical and evolutionarily (at least from mouse to human) highly conserved protein/protein interaction decision point in stem cells 27, 28, 31, 45 may provide a unique advantage with regards to drug resistance. Translationally, the unique ability of CBP/catenin antagonists to initiate the differentiation of drug-resistant tumorinitiating cells in multiple mouse models (genetic and primary patient cell engraftment) without any apparent deleterious effects on the normal endogenous stem cell populations provides a new paradigm to effectively treat and eliminate tumor-initiating cells in a wide range of malignancies. 46, 47 The recently developed second-generation CBP/catenin antagonist PRI-724 (IC 50~1 50 nM) has proven extremely safe in both IND (investigational new drug)-enabling toxicology studies and in a Phase Ia clinical trial. In the IND-enabling toxicology study, the NOAEL (no adverse effect dose level) in dogs given continuous intravenous administration for 28 days was 120 mg/Kg/day with sustained plasma levels 4200 times the IC 50. Furthermore, in the Phase Ia clinical trial for solid tumors, no maximum tolerated dose was reached with escalation from 40 to 1280 mg/m 2 /day with continuous infusion intravenously for 7 days. In addition, an inverse relationship was observed between dose level and survivin/BIRC5 expression in patient circulating tumor cells. 48 The results reported here, in conjunction with the safety of CBP/catenin antagonists in the clinic to date, augur well for a new therapeutic paradigm to safely eliminate drug-resistant tumor-initiating cells. Clinical studies to evaluate this strategy are currently underway (www.clinicaltrials.gov NCT01606579).
MATERIALS AND METHODS
Cell culture and CML patient samples
Human CML cell lines K562, K562R (IM resistant), EM2 and M2-10B4 stromal cells were purchased from ATCC (Manassas, VA, USA) and cultured in RPMI 1640 medium (Life Technologies Inc., Grand Island, NY, USA) supplemented with 10% fetal bovine serum (GE Healthcare Life Sciences, Logan, UT, USA). Cells were maintained at 37°C, 5% CO 2 in a humidified incubator. K562R cells were cultured with medium containing 1 μM IM. For in vivo studies, both EM2 and K562 cells were labeled with a lentiviral vector expressing firefly luciferase and green fluorescent protein (GFP) with pCCL-c-MNDU3c-LUC-PGK-EGFP viral supernatant. For high titer production of viral supernatant, the lentiviral expression plasmid was cotransfected using calcium chloride precipitation into HEK293T cells together with plasmid pMDG and pCMVΔ8.91. Transduced EM2 and K562 cells were FACS sorted for GFP bright population.
All samples from CML patients (bone marrow or peripheral blood) were obtained with written informed consent, and the study was conducted according to the regulations of the institutional review board of the University of Southern California, Keck School of Medicine. Six BC, 5 IM-R, and 9 CP patients' samples were used in the study. Detailed de-identified patients' information is summarized in Supplementary Table S2 . Primary CML cells were cultured in QBSF-60 medium (Quality Biological Inc., Gaithersburg, MD, USA) at a seeding concentration of 1-1.5 × 10 6 /ml. Dead cells were removed using a Dead Cell Removal Kit (Miltenyi Biotec, San Diego, CA, USA) before treatment.
CFC assay and SP cell assay
Stromal cells were irradiated at 8000 rad and then plated at 3 × 10 5 per well in six-well plates. Then 1000 sorted IM-R or IM-S cells were co-cultured with stromal cells in Stem Pro-34 SFM (Life Technologies) supplemented with the following human growth factors: Arg-1 100 ng/ml, TPO 300 ng/ml, Flt3
Pharmacological CML stem cell elimination Y Zhao et al 300 ng/ml, stem cell factor 300 ng/ml, granulocyte colony-stimulating factor 10 ng/ml, interleukin (IL)-3 10 ng/ml, and IL-6 10 ng/ml (PeproTech, Rocky Hill, NJ, USA). Cells were recovered for BCR-ABL expression or CFC assay.
CFC assays were performed according to the manufacturer's instructions. Briefly, cells were plated in triplicate on dishes containing methylcellulose medium (Methocult H4435, StemCell Technologies, Vancouver, Canada). Cells were pretreated with different compounds or different compounds were added into the methylcellulose medium, and 1000 (DMSO) to 2000 (ICG-001 or IM or ICG-001/IM) cells were plated. The plates were incubated at 37°C with 5% CO 2 . Total colony numbers were counted 14 days after plating.
SP assay was performed as previously described. 49 Cells were pretreated with DMSO or ICG-001 (10 μM) for 24 h before SP assay analysis was performed.
FACS analysis/sorting
Antibodies and isotype controls for immunostaining were purchased from eBioscience (San Diego, CA, USA): anti-human CD45 (clone 2D1, Cat. no. 8011-9459), CD11b (clone 1CRF44, Cat. no. 47-0118), CD16 (clone CB16, Cat. no. 9011-0168), CD33 (clone HIM3-4, Cat. no. 12-0339), CD56 (clone CMSSB, Cat. no. 17-0567), CD41 (clone HIP8, Cat. no. 9011-0419) and CD61 (VI-PL2, Cat. no. 17-0619), anti-BrdU (clone BU20A, Cat. no. 11-5071), and anti-ki67 (20Raj1, Cat. no. 12-5699). Cell staining was performed according to the manufacturer's instructions and analyzed with a BD LSR Fortessa. To sort IM-R and IM-S cells, CML samples were treated with IM (1 or 5 μM) for 4-6 days after which the cells were sorted using a BD AriaII Flow Cytometer. Annexin V and Caspase 3 analyses were performed according to the manufacturer's instructions (BD Biosciences, San Jose, CA, USA).
Synthesis of ICG-001
ICG-001 was synthesized as previously described. 24 RNA isolation and RT-PCR Total RNA was isolated with Trizol (Life Technologies) according to the manufacturer's instructions and then treated with DNase before cDNA synthesis (iScript TM cDNA Synthesis Kit, Bio-Rad, Hercules, CA, USA). qRT-PCR was performed with the SYBR Green PCR Master Mix Kit (Bio-Rad) using the following primers: human survivin F 5′-AGCCCTTTCAAGGACCAC-3′, R 5′-GGATCTTCATGAGGTAGTCAGTC-3′; BCR-ABL F 5′-GAGTCTCCGGGGCT CTATGG-3′, R 5′-GCCGCTGAAGGGCTTTTGAA-3′; human GusB F 5′-CGTCC CACCTAGAATCTGCT-3′, R 5′-TTGCTCACAAAGGTCACAGG-3′; and human glyceraldehyde 3-phosphate dehydrogenase (GAPDH) F 5′-GGTGCTGAGT ATGTCGTGGA-3′, R 5′-ACAGTCTTCTGGGTGGCAGT-3′. All results were normalized to the housekeeping gene GAPDH or Gus-B, and the expression was compared with control-treated cells. Quantitation of gene expression was based on the cycle threshold (Ct) value for each sample. Delta Ct was calculated as (gene of interest Ct) − (housekeeping gene Ct). The relative quantity of mRNA expression was calculated by delta-delta Ct calculation as (treated sample delta Ct) − (control sample delta Ct). All experiments included negative controls consisting of no cDNA for each primer pair. Data represent the mean of at least two independent experiments (± s.d.).
Immunoprecipitation and immunoblotting
Immunoprecipitation and immunoblotting were performed as described previously. 24 Briefly, cell lysates (50-100 μg protein) were incubated with protein A agarose (Roche Applied Science, Mannheim, Germany) for 1 h. The precleared samples were then incubated with specific antibodies at 4°C overnight. Normal rabbit IgG was used as negative control. Protein A agarose beads were incubated with protease inhibitors. The immunocomplexes were washed and separated on a 4-20% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gradient gel (Invitrogen, Carlsbad, CA, USA) and analyzed by immunoblot. The antibodies utilized were CBP/p300 (Santa Cruz Biotechnology Inc., Dallas, TX, USA; SC-32244), anti-β-catenin (BD Bioscience, Cat. no. 610153) and anti-γ-catenin (BD Biosciences, Cat. no. 610253). Antibodies for immunoblotting (50 μg total protein) were anti-BCR-ABL (clone 131), anti-CBP (clone SC-369), anti-p300 (clone SC-584), anti-survivin (clone SC-10811), all from Santa Cruz Biotechnology. Anti-α-tubulin (clone CP06) was from Calbiotech (Spring Valley, CA, USA). UN-SCAN-IT software (Silk Scientific, Orem, UT, USA) was used to quantify the protein bands normalized to α-tubulin.
ChIP analysis of CBP/p300 occupancy at the human survivin promoter ChIP analysis was performed as previously described. 10 In brief, K562 cells were cultured in T25 flasks with approximately 15 million cells in 10 ml of complete growth medium containing DMSO, 10 μM, or 20 μM ICG-001 for 24 h prior to cross-linking with 1% formaldehyde. Cells were then lysed and sonicated. Normal IgG (Santa Cruz, sc-2027), anti-CBP (A22, Santa Cruz, sc-369) or anti-p300 (N15, Santa Cruz, sc-584) were then added to the sheared chromatin. After 24 h, agarose beads were added, and DNA was eluted from beads. One-tenth of the elution was used for qPCR analysis on a BioRad MyIQ RT-PCR detection system (Hercules, CA, USA). The occupancy of CBP or p300 at the survivin promoter was determined by the Fold Enrichment Method (ThermoFisher Science, Waltham, MA, USA, ChIP analysis). The primers used in the study were: forward: hu-Survivin ChIP-F 5′-CTCCAGGACTCAAGTGATGC-3′; and reverse: hu-Survivin ChIP-R 5′-CCGCGGCCTTCTGGGAGTAG-3′.
Animal studies
All animal studies were approved by the USC institutional IACUC committee. NOD.Cg-Prkdc scid il2rg tm1wji /SzJ (NSG) mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA) and subsequently bred and maintained at the University of Southern California animal facility. Female mice aged 8-10 weeks were used in the study. Animals were randomly assigned to each treatment group. Investigators were not blinded in the animal studies. Transduced EM2 or K562 cells were injected via tail vein into sublethally irradiated (300 cGy) NSG mice. Under general anesthesia with isoflurane, leukemia progression was monitored via in vivo utilizing an IVIS 100 bioluminescence/optical imaging system (Xenogen Corporation, Alameda, CA, USA). D-luciferin (Promega, Madison, WI, USA) dissolved in PBS was injected intraperitoneally at a dose of 2.5 mg/mouse, 15 min before luminescence signal measurement. After confirmation of leukemia engraftment, mice received either saline/saline, Nilotinib/saline (100 mg/Kg/day) or a combination of ICG-001 (50 mg/Kg/day) and Nilotinib (100 mg/Kg/day) treatment.
For the primary CML patients' sample study, leukemia cells were injected via tail vein into 300 cGy irradiated NSG mice, and blood was collected for FACS analysis of human CD45-positive leukemia cells after 14 days to confirm leukemia engraftment. At the end of the experiment, mice were killed and the bone marrow, blood, and spleen were collected for FACS analysis of human CD45-positive cells. To measure blood counts, mouse blood was collected in BD microtainer tubes with EDTA and analyzed with a Hemavet (Drew Scientific Inc., Miami, FL, USA). ICG-001 was delivered via Alzet osmotic minipump (model 1004, Alzet, Cupertino, CA, USA) according to the manufacturer's instructions.
Statistical analysis
Student's t-test or log-rank (Kaplan-Meier) test was performed using GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA, USA). A minimum of three individual CML samples were used in gene expression and colony assays, with at least two technical repeats (Supplementary Tables).
